CN1836042A - 用于基因沉默的hbv和hcv保守序列 - Google Patents

用于基因沉默的hbv和hcv保守序列 Download PDF

Info

Publication number
CN1836042A
CN1836042A CNA2004800228949A CN200480022894A CN1836042A CN 1836042 A CN1836042 A CN 1836042A CN A2004800228949 A CNA2004800228949 A CN A2004800228949A CN 200480022894 A CN200480022894 A CN 200480022894A CN 1836042 A CN1836042 A CN 1836042A
Authority
CN
China
Prior art keywords
seq
sequence
hbv
virus
rna
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2004800228949A
Other languages
English (en)
Chinese (zh)
Inventor
C·J·帕楚克
C·萨蒂什钱德兰
V·R·小祖劳斯基
L·明茨
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nucleonics Inc
Original Assignee
Nucleonics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nucleonics Inc filed Critical Nucleonics Inc
Publication of CN1836042A publication Critical patent/CN1836042A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C12N2310/531—Stem-loop; Hairpin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)
CNA2004800228949A 2003-06-12 2004-06-10 用于基因沉默的hbv和hcv保守序列 Pending CN1836042A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US47807603P 2003-06-12 2003-06-12
US60/478,076 2003-06-12

Publications (1)

Publication Number Publication Date
CN1836042A true CN1836042A (zh) 2006-09-20

Family

ID=34135047

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2004800228949A Pending CN1836042A (zh) 2003-06-12 2004-06-10 用于基因沉默的hbv和hcv保守序列

Country Status (13)

Country Link
US (1) US8350021B2 (OSRAM)
EP (4) EP3470518A1 (OSRAM)
JP (2) JP4980716B2 (OSRAM)
CN (1) CN1836042A (OSRAM)
AU (1) AU2004263832B2 (OSRAM)
BR (1) BRPI0411219A (OSRAM)
CA (2) CA3040025C (OSRAM)
DK (1) DK2270162T3 (OSRAM)
HU (1) HUE042261T2 (OSRAM)
IL (1) IL172268A0 (OSRAM)
SG (1) SG173218A1 (OSRAM)
SI (1) SI2270162T1 (OSRAM)
WO (1) WO2005014806A2 (OSRAM)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107683336A (zh) * 2015-05-06 2018-02-09 贝尼泰克生物制药有限公司 用于治疗乙型肝炎病毒(hbv)感染的试剂及其用途
WO2019051812A1 (zh) * 2017-09-15 2019-03-21 深圳华大智造科技有限公司 确定预定染色体保守区域的方法、确定样本基因组中是否存在拷贝数变异的方法、系统和计算机可读介质

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3040025C (en) 2003-06-12 2023-01-10 Alnylam Pharmaceuticals, Inc. Conserved hbv and hcv sequences useful for gene silencing
US8575327B2 (en) 2003-06-12 2013-11-05 Alnylam Pharmaceuticals, Inc. Conserved HBV and HCV sequences useful for gene silencing
JP5243789B2 (ja) 2004-03-15 2013-07-24 シティ・オブ・ホープ 二本鎖ｒｎａによる遺伝子発現の特異的阻害のための方法及び組成物
US20070265220A1 (en) 2004-03-15 2007-11-15 City Of Hope Methods and compositions for the specific inhibition of gene expression by double-stranded RNA
WO2006033756A2 (en) 2004-08-23 2006-03-30 Nucleonics, Inc. Multiple rna polymerase iii promoter expression constructs
EP2325314B1 (en) 2004-09-24 2014-08-20 Alnylam Pharmaceuticals, Inc. Targeting opposite strand replication intermediates of single-stranded viruses by RNAI
AU2005319306B9 (en) * 2004-12-22 2012-04-05 Alnylam Pharmaceuticals, Inc. Conserved HBV and HCV sequences useful for gene silencing
WO2011103394A2 (en) * 2010-02-19 2011-08-25 Agave Pharma Inc. Methods for gene inhibition
WO2011109380A1 (en) * 2010-03-01 2011-09-09 The Children's Hospital Of Philadelphia Nucleic acids for targeting multiple regions of the hcv genome
LT2606134T (lt) * 2010-08-17 2019-07-25 Sirna Therapeutics, Inc. Hepatito b viruso (hbv) geno raiškos slopinimas, tarpininkaujant rnr interferencijai naudojant mažą interferuojančią nukleorūgštį (sina)
EP3505528B1 (en) 2011-04-21 2020-11-25 Ionis Pharmaceuticals, Inc. Modulation of hepatitis b virus (hbv) expression
CA2883785C (en) 2012-08-30 2020-08-18 Replicor Inc. Methods for the treatment of hepatitis b and hepatitis d infections
CN105555303A (zh) 2013-06-28 2016-05-04 贝勒研究院 用于多发性硬化症的树突细胞asgpr靶向免疫治疗剂
SG10201804975PA (en) 2013-12-12 2018-07-30 Broad Inst Inc Delivery, Use and Therapeutic Applications of the Crispr-Cas Systems and Compositions for HBV and Viral Diseases and Disorders
JOP20200092A1 (ar) 2014-11-10 2017-06-16 Alnylam Pharmaceuticals Inc تركيبات iRNA لفيروس الكبد B (HBV) وطرق لاستخدامها
WO2017015175A1 (en) 2015-07-17 2017-01-26 Arcturus Therapeutics, Inc. Compositions and agents against hepatitis b virus and uses thereof
US20170137821A1 (en) 2015-07-17 2017-05-18 Arcturus Therapeutics, Inc. Molecules and agents for treating hepatitis b virus
HUE053172T2 (hu) 2016-03-14 2021-06-28 Hoffmann La Roche Oligonukleotidok a PD-L1 expresszió csökkentésére
MA45496A (fr) 2016-06-17 2019-04-24 Hoffmann La Roche Molécules d'acide nucléique pour la réduction de l'arnm de padd5 ou pad7 pour le traitement d'une infection par l'hépatite b
EP3548005A4 (en) 2016-11-29 2020-06-17 Puretech Health LLC Exosomes for delivery of therapeutic agents
US11324820B2 (en) 2017-04-18 2022-05-10 Alnylam Pharmaceuticals, Inc. Methods for the treatment of subjects having a hepatitis b virus (HBV) infection
CN118048356A (zh) 2017-10-16 2024-05-17 豪夫迈·罗氏有限公司 减少PAPD5和PAPD7 mRNA的核酸分子用于治疗乙型肝炎感染
MA52661A (fr) 2018-04-05 2021-02-17 Centre Leon Berard Utilisation d'inhibiteurs de fubp1 dans le traitement d'une infection par le virus de l'hépatite b
PE20210346A1 (es) 2018-07-03 2021-02-25 Hoffmann La Roche Oligonucleotidos para modular la expresion de tau
AU2019300324A1 (en) 2018-07-13 2021-01-21 F. Hoffmann-La Roche Ag Oligonucleotides for modulating RTEL1 expression
EP3837366A1 (en) 2018-08-13 2021-06-23 Alnylam Pharmaceuticals, Inc. Hepatitis b virus (hbv) dsrna agent compositions and methods of use thereof
WO2021122910A1 (en) 2019-12-19 2021-06-24 F. Hoffmann-La Roche Ag Use of sbds inhibitors for treating hepatitis b virus infection
JP7653997B2 (ja) 2019-12-19 2025-03-31 エフ． ホフマン－ラ ロシュ アーゲー Ｂ型肝炎ウイルス感染を処置するためのｃｏｐｓ３阻害剤の使用
JP2023506540A (ja) 2019-12-19 2023-02-16 エフ． ホフマン－ラ ロシュ エージー． Ｂ型肝炎ウイルス感染を処置するためのｓｃａｍｐ３阻害剤の使用
WO2021122735A1 (en) 2019-12-19 2021-06-24 F. Hoffmann-La Roche Ag Use of sept9 inhibitors for treating hepatitis b virus infection
JP2023506954A (ja) 2019-12-19 2023-02-20 エフ． ホフマン－ラ ロシュ エージー． Ｂ型肝炎ウイルス感染を処置するためのｓａｒａｆ阻害剤の使用
CN116157522A (zh) 2020-08-21 2023-05-23 豪夫迈·罗氏有限公司 A1cf抑制剂用于治疗乙型肝炎病毒感染的用途
TW202246500A (zh) 2021-02-02 2022-12-01 瑞士商赫孚孟拉羅股份公司 用於抑制 ｒｔｅｌ１ 表現之增強型寡核苷酸
JP2024546993A (ja) 2021-12-17 2024-12-26 エフ． ホフマン－ラ ロシュ アーゲー Ｒｔｅｌ１及びｆｕｂｐ１を調節するためのオリゴヌクレオチドの組み合わせ

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5643771A (en) 1980-05-19 1997-07-01 The Board Of Trustees Of The Leland Stanford Junior University Non-reverting live bacterial vaccines
US4897355A (en) 1985-01-07 1990-01-30 Syntex (U.S.A.) Inc. N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
EP0732397A3 (en) 1988-02-05 1996-10-23 Whitehead Institute For Biomedical Research Modified hepatocytes and uses therefor
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5279833A (en) 1990-04-04 1994-01-18 Yale University Liposomal transfection of nucleic acids into animal cells
US5264618A (en) 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
JPH05507203A (ja) 1990-06-18 1993-10-21 アメリカ合衆国 真核性発現ベクター系
US5283185A (en) 1991-08-28 1994-02-01 University Of Tennessee Research Corporation Method for delivering nucleic acids into cells
US20030206887A1 (en) * 1992-05-14 2003-11-06 David Morrissey RNA interference mediated inhibition of hepatitis B virus (HBV) using short interfering nucleic acid (siNA)
US5593972A (en) 1993-01-26 1997-01-14 The Wistar Institute Genetic immunization
US5739118A (en) 1994-04-01 1998-04-14 Apollon, Inc. Compositions and methods for delivery of genetic material
WO1995030746A1 (en) * 1994-05-10 1995-11-16 The General Hospital Corporation Antisense inhibition of hepatitis c virus
JPH07303485A (ja) * 1994-05-13 1995-11-21 Tonen Corp Ｈｃｖアンチセンスｒｎａ、それを含む発現ベクター、及び該ｒｎａ又は発現ベクターを含むｈｃｖ関連疾患治療剤
US5646262A (en) * 1994-07-28 1997-07-08 Georgetown University Antisense oligonucleotides against hepatitis B viral replication
US5837533A (en) 1994-09-28 1998-11-17 American Home Products Corporation Complexes comprising a nucleic acid bound to a cationic polyamine having an endosome disruption agent
US5571026A (en) * 1994-12-09 1996-11-05 Kcs Industries, Inc. Flat mount electrode socket
US6057153A (en) * 1995-01-13 2000-05-02 Yale University Stabilized external guide sequences
US5877159A (en) 1995-05-03 1999-03-02 University Of Maryland At Baltimore Method for introducing and expressing genes in animal cells and live invasive bacterial vectors for use in the same
US5932241A (en) 1995-06-07 1999-08-03 Valentis, Incorporated Cationic lipid DNA complexes for gene targeting
US5824538A (en) 1995-09-06 1998-10-20 The United States Of America As Represented By The Secretary Of The Army Shigella vector for delivering DNA to a mammalian cell
US5843770A (en) * 1996-03-11 1998-12-01 The Immune Response Corporation Antisense constructs directed against viral post-transcriptional regulatory sequences
US5877162A (en) * 1996-03-14 1999-03-02 Innovir Laboratories, Inc. Short external guide sequences
US6610478B1 (en) * 1996-08-16 2003-08-26 Yale University Phenotypic conversion of cells mediated by external guide sequences
US5981274A (en) * 1996-09-18 1999-11-09 Tyrrell; D. Lorne J. Recombinant hepatitis virus vectors
US6217900B1 (en) 1997-04-30 2001-04-17 American Home Products Corporation Vesicular complexes and methods of making and using the same
DE19725803C1 (de) * 1997-06-18 1999-02-11 Deutsches Krebsforsch HBV-gerichtete Antisense-Nukleinsäuren
CA2306733A1 (en) 1997-10-28 1999-05-06 American Home Products Corporation Compositions and methods for delivery of genetic material
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
AU747140B2 (en) * 1998-01-27 2002-05-09 British Biocell International Limited Method for detection of nucleic acid target sequences involving (in vitro) transcription from an RNA promoter
KR20010041902A (ko) 1998-03-16 2001-05-25 데이비드 엠 모이어 포유류의 피부 내의 셀룰라이트를 감소시키는 방법
BR0009884A (pt) 1999-04-21 2002-01-08 American Home Prod Processos e composições para a inibição da função das sequências de polinucleotìdeos
US6533250B2 (en) 1999-10-15 2003-03-18 W. Eugene Arthur Energy dissipating system for a concrete roadway barrier
WO2003070918A2 (en) * 2002-02-20 2003-08-28 Ribozyme Pharmaceuticals, Incorporated Rna interference by modified short interfering nucleic acid
EP1309726B2 (en) * 2000-03-30 2018-10-03 Whitehead Institute For Biomedical Research Rna sequence-specific mediators of rna interference
US7439016B1 (en) * 2000-06-15 2008-10-21 Digene Corporation Detection of nucleic acids by type-specific hybrid capture method
US6680059B2 (en) * 2000-08-29 2004-01-20 Tripep Ab Vaccines containing ribavirin and methods of use thereof
US6443403B1 (en) 2000-09-11 2002-09-03 Panduit Corp. Cable routing clamp and method of application
JP2002335968A (ja) * 2001-05-16 2002-11-26 Kokuritsu Iyakuhin Shokuhin Eisei Kenkyusho 新規転写因子、その遺伝子及びその結合ｄｎａ配列
JP4210737B2 (ja) 2001-07-12 2009-01-21 ユニバーシティー オブ マサチューセッツ 遺伝子サイレンシングを仲介する低分子干渉リボ核酸のインビボにおける製造方法
WO2003013293A2 (en) 2001-08-03 2003-02-20 Michael Van Der Sleesen Protective garment
US7103761B2 (en) 2001-08-07 2006-09-05 Hewlett-Packard Development Company, Lp. Server system with multiple management user interfaces
US6673661B1 (en) 2002-12-20 2004-01-06 Taiwan Semiconductor Manufacturing Co., Ltd. Self-aligned method for forming dual gate thin film transistor (TFT) device
EP1591524A4 (en) 2003-01-24 2007-12-26 Tokyo Metropolitan Org Med Res OLIGORIBONUCLEOTIDE OR PEPTIDIC NUCLEIC ACID, THE BZW. THE FUNCTION OF THE HEPATITIS C-VIRUS HEMMT
CN1257284C (zh) 2003-03-05 2006-05-24 北京博奥生物芯片有限责任公司 一种体外阻断乙肝病毒表达的方法
CA3040025C (en) 2003-06-12 2023-01-10 Alnylam Pharmaceuticals, Inc. Conserved hbv and hcv sequences useful for gene silencing
WO2006033756A2 (en) * 2004-08-23 2006-03-30 Nucleonics, Inc. Multiple rna polymerase iii promoter expression constructs
JP2015086965A (ja) 2013-10-31 2015-05-07 株式会社エクセディ フライホイール組立体

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107683336A (zh) * 2015-05-06 2018-02-09 贝尼泰克生物制药有限公司 用于治疗乙型肝炎病毒(hbv)感染的试剂及其用途
WO2019051812A1 (zh) * 2017-09-15 2019-03-21 深圳华大智造科技有限公司 确定预定染色体保守区域的方法、确定样本基因组中是否存在拷贝数变异的方法、系统和计算机可读介质

Also Published As

Publication number Publication date
EP1631670A2 (en) 2006-03-08
DK2270162T3 (en) 2019-01-21
CA3040025A1 (en) 2005-02-17
CA3040025C (en) 2023-01-10
US20080070854A1 (en) 2008-03-20
WO2005014806A2 (en) 2005-02-17
EP3470518A1 (en) 2019-04-17
AU2004263832B2 (en) 2010-07-01
SI2270162T1 (sl) 2019-03-29
EP2270162A3 (en) 2012-05-30
EP2284268A2 (en) 2011-02-16
IL172268A0 (en) 2006-04-10
BRPI0411219A (pt) 2006-07-18
EP2270162A2 (en) 2011-01-05
US8350021B2 (en) 2013-01-08
WO2005014806A3 (en) 2005-12-01
EP1631670B1 (en) 2012-08-08
CA2528510C (en) 2019-06-04
SG173218A1 (en) 2011-08-29
JP2011224013A (ja) 2011-11-10
EP2284268A3 (en) 2012-05-30
CA2528510A1 (en) 2005-02-17
EP2270162B1 (en) 2018-10-03
JP4980716B2 (ja) 2012-07-18
HUE042261T2 (hu) 2019-06-28
JP5593279B2 (ja) 2014-09-17
JP2007503474A (ja) 2007-02-22
AU2004263832A1 (en) 2005-02-17

Similar Documents

Publication Publication Date Title
CN1836042A (zh) 用于基因沉默的hbv和hcv保守序列
CN1617929A (zh) siRNA表达系统和利用该系统制备功能性基因击倒细胞的方法
CN1675359A (zh) 其它新形式的干扰rna分子
CN101052717A (zh) 诱发rna干扰的多核苷酸以及使用该多核苷酸的基因表达抑制方法
CN101031579A (zh) 胰岛小rna及抑制其的方法
CN101044152A (zh) 组合RNAi治疗的方法和组合物
CN1738648A (zh) 小干扰rna基因治疗
CN1630535A (zh) Stat－1之抑制
CN1788086A (zh) 抗Smad7的反义寡核苷酸(ODN)及其在医药领域中的用途
CN1526818A (zh) 一种阻断乙肝病毒表达的方法
CN1833024A (zh) 含有衍生自基因型2a丙肝病毒(HCV)基因组的核酸的核酸构建体和具有转移入其中的这样的核酸构建体的细胞
CN1703229A (zh) 治疗前列腺和其他癌的组合物和方法
CN101065501A (zh) 确定基因毒性的方法
CN1665930A (zh) 具有RNAi效应的茎环RNA分子的表达系统
CN1276083C (zh) 用体内产生的ssDNA改变基因表达
CN1812797A (zh) 双链核糖核酸在诱导细胞裂解中的应用
CN1904900A (zh) 人类的内源性siRNA序列及其应用和筛选方法
CN1934256A (zh) 针对滑膜蛋白基因启动子的诱杀核酸
Sun et al. Quantitative assessment of the antiviral potencies of 21 shRNA vectors targeting conserved, including structured, hepatitis B virus sites
CN1977044A (zh) 治疗胰腺癌的组合物和方法
CN1566131A (zh) 攻击人类乙型肝炎病毒的小干扰RNA分子（SiRNA）及其应用
CN1809583A (zh) 抑制hif－1表达的反义寡核苷酸
CN1910293A (zh) 检测与抗病毒感染性有关的基因oas1中的突变的方法
CN1780913A (zh) 哺乳动物细胞中dsRNA诱导CpG序列甲基化
CN1909927A (zh) 抑制癌的方法

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication